Investing.com - Pfizer (NYSE:PFE) reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Pfizer announced earnings per share of $1.34 on revenue of $24.09B. Analysts polled by Investing.com anticipated EPS of $1.08 on revenue of $22.56B.
Pfizer shares are up 18% from the beginning of the year, still down 15.85% from its 52 week high of $51.86 set on August 18. They are under-performing the S&P Global 100 which is up 19.28% from the start of the year.
Pfizer follows other major Healthcare sector earnings this month
Pfizer's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on October 27 with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.38B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in PFE right now?
With PFE making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed PFE alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including PFE, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is PFE poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now